Treat and Reduce Obesity Act of 2025
- Bill Number
- S. 1973
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-05: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-02-24T12:03:19Z
AI-Generated Summary
Purpose
The Treat and Reduce Obesity Act of 2025 aims to improve Medicare coverage for obesity prevention and treatment by expanding access to behavioral therapies and medications. It seeks to address the growing obesity epidemic among older adults, which increases chronic diseases, healthcare costs, and mortality, by coordinating federal programs and enhancing care options under Medicare (the federal health insurance program for people aged 65 and older, some younger people with disabilities, and those with certain conditions).
Key Provisions
- Findings on Obesity (Section 2): The bill outlines Congress's recognition of obesity as a major public health issue, citing statistics such as 41% of adults over 60 having obesity (affecting over 27 million people), its role as the second leading cause of death (300,000 annually), links to chronic conditions like heart disease and diabetes, and rising Medicare costs ($50 billion in 2014 for obese beneficiaries). It projects that nearly half of Medicare beneficiaries could have obesity by 2030 if trends continue.
- Expansion of Providers for Behavioral Therapy (Section 3): Amends Medicare rules to allow more types of healthcare providers to deliver "intensive behavioral therapy" (structured counseling to change eating and activity habits) for obesity. Eligible providers include:
- Non-primary care physicians.
- Physician assistants, nurse practitioners, clinical nurse specialists, clinical psychologists, registered dietitians, or nutrition professionals.
- Approved community-based lifestyle counseling programs.
- Therapy must be referred by a physician or primary care provider, coordinated with them (including sharing recommendations), and delivered in approved settings like offices, hospitals, or privacy-compliant community sites.
- Coverage of Obesity Medications Under Medicare Part D (Section 4): Removes the exclusion for prescription drugs used to treat obesity or manage weight loss in overweight individuals with related health issues (e.g., high blood pressure or diabetes). This applies to Medicare Part D (the optional drug benefit program). Coverage begins 2 years after the bill's enactment.
- Reporting Requirements (Section 5): The Secretary of Health and Human Services (HHS) must submit reports to Congress starting 1 year after enactment, and every 2 years thereafter. Reports will detail implementation steps and recommend ways to better coordinate HHS programs and other federal efforts for obesity research, clinical care, and prevention, including interactions between doctors, providers, and patients.
Significant Changes to Existing Law
- Broader Provider Access: Previously, Medicare limited intensive behavioral therapy for obesity to primary care physicians and certain practitioners. This bill expands it to a wider range of professionals and community programs, promoting collaborative care but requiring physician referrals and coordination to maintain oversight.
- Inclusion of Obesity Drugs in Part D: Current law excludes drugs primarily for obesity or weight loss from Part D coverage (similar to exclusions for cosmetics or fertility treatments). The bill lifts this for obesity-specific uses, potentially adding these medications to standard formularies (lists of covered drugs) while tying eligibility to medical need (e.g., comorbidities like type 2 diabetes).
These changes amend title XVIII of the Social Security Act, which governs Medicare, without altering other parts of the program.
Potential Impacts
- On Medicare Beneficiaries: Increased access to therapies and drugs could help more older adults (especially the 41% with obesity) manage weight, reduce chronic disease risks, and extend life expectancy (e.g., potentially reversing the 1.4–1.6 year loss noted in findings). It may lower out-of-pocket costs for treatments, benefiting low-income or rural enrollees.
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS, under HHS) will need to update coverage rules, approve providers/programs, and monitor coordination, possibly increasing short-term administrative costs. Long-term, it could reduce overall Medicare spending (currently $2,018 more per obese beneficiary annually) by preventing complications, though initial drug coverage might raise Part D expenditures.
- On Citizens and Healthcare System: Could encourage preventive care nationwide, indirectly benefiting non-Medicare adults through broader research and program coordination. Pharmaceutical costs for obesity drugs (e.g., GLP-1 agonists like semaglutide) may rise federally, but evidence-based approaches might curb the $427.8 billion annual obesity economic burden.
- On International Relations: Minimal direct impact, as this is a domestic health policy focused on U.S. Medicare; however, it could influence global obesity research collaborations via HHS recommendations.
Main Stakeholders Affected
- Medicare Beneficiaries: Primarily adults 65+ with obesity or overweight plus comorbidities, who gain expanded treatment options.
- Healthcare Providers: Physicians, nurse practitioners, psychologists, dietitians, and community programs benefit from new reimbursement opportunities but must adhere to referral and coordination rules.
- Government Entities: HHS and CMS, responsible for implementation, reporting, and program oversight; Congress, via required updates.
- Pharmaceutical Industry: Companies producing obesity medications (e.g., for weight loss) could see increased Medicare sales and market expansion.
- Advocacy and Community Groups: Organizations focused on public health, chronic disease prevention, and nutrition, which may participate in or influence approved lifestyle programs.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Strengthens Medicare's role in preventive care by interpreting obesity as a treatable condition warranting coverage, potentially setting precedents for expanding benefits under the Social Security Act. It emphasizes evidence-based programs and HIPAA-compliant privacy (Health Insurance Portability and Accountability Act rules for protecting health information), ensuring therapies meet federal standards without creating new mandates on private insurers.
- Constitutional Implications: None significant; the bill operates within Congress's authority under the Spending Clause (Article I, Section 8) to regulate federal programs like Medicare, promoting general welfare through health initiatives.
- Political Implications: Bipartisan support (introduced by Sen. Cassidy with 19 cosponsors from both parties) highlights obesity as a non-partisan crisis, potentially easing passage in a divided Congress. It promotes inter-agency coordination, which could foster future health policies, but faces scrutiny over costs amid debates on Medicare sustainability. The 2-year delay for drug coverage allows time for fiscal analysis, balancing access with budgetary concerns.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (22)
Sen. Luján, Ben Ray [D-NM], Sen. Tillis, Thomas [R-NC], Sen. Padilla, Alex [D-CA], Sen. Blackburn, Marsha [R-TN], Sen. Fetterman, John [D-PA], Sen. Capito, Shelley Moore [R-WV], Sen. Gallego, Ruben [D-AZ], Sen. Hyde-Smith, Cindy [R-MS], Sen. Peters, Gary C. [D-MI], Sen. Wicker, Roger F. [R-MS], Sen. Klobuchar, Amy [D-MN], Sen. Booker, Cory A. [D-NJ], Sen. Blumenthal, Richard [D-CT], Sen. Heinrich, Martin [D-NM], Sen. Van Hollen, Chris [D-MD], Sen. Coons, Christopher A. [D-DE], Sen. Shaheen, Jeanne [D-NH], Sen. Budd, Ted [R-NC], Sen. Warnock, Raphael G. [D-GA], Sen. Merkley, Jeff [D-OR], Sen. Alsobrooks, Angela D. [D-MD], Sen. Duckworth, Tammy [D-IL]
Recent Actions
- 2025-06-05: Read twice and referred to the Committee on Finance.
- 2025-06-05: Introduced in Senate
Bill Versions
- Treat and Reduce Obesity Act of 2025 — issued 2025-06-05 — PDF (6 pages)